X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.
Lead Product(s): PAN004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PAN004
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pantherna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 07, 2024
Details:
The collaboration aims for the development and production of Noregen (CTR-107), a novel regenerative therapeutic, for treating retinal-related vision loss. CTR-107 is the first program to obtain FDA Rare Pediatric Disease Designation for Familial Exudative Vitreoretinopathy.
Lead Product(s): CTR-107
Therapeutic Area: Rare Diseases and Disorders Product Name: Noregen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Caeregen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2023
Details:
Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: CureVac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
